Cardunolizumab for advanced vulvar or vaginal cancer
Part of Cancer, Women’s health & pregnancy clinical trials.
This study is testing a new drug called cardunolizumab for people with advanced vulvar or vaginal cancer that has come back or spread. The goal is to see if the drug can shrink tumors or slow the cancer's growth.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 to 75 years old.
- You have vulvar or vaginal cancer that has come back or spread and cannot be cured with standard treatments.
- Your cancer is one of these types: squamous cell, adenocarcinoma, or adenosquamous carcinoma.
- You have at least one tumor that can be measured on a scan.
- You are able to take care of yourself (up and about, with only light restrictions).
- You are willing to provide a tissue sample from a past biopsy or surgery.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a combination of two drugs, pembrolizumab (an immunotherapy) and lenvatinib (a targeted therapy), for women with advanced vulvar cancer that cannot be surgically removed or has spread. The goal is to see if this combination can shrink or control the cancer.
This trial tests whether combining pembrolizumab with lenvatinib can shrink and control advanced vulvar squamous cell cancer that can’t be fully treated with surgery or strong radiation. It may help some people live longer and better control symptoms, but it also requires close monitoring and specific health criteria.
This trial tests a combination of an immunotherapy drug (Caronizumab) and a special type of low-dose radiation (PLDR) for people with esophageal, lung, or cervical cancer that has come back or spread after initial treatment. It aims to see if the combination can help stop the cancer from growing.
This trial tests combining two drugs, nivolumab (an immunotherapy) and imiquimod (a cream that boosts the immune system), to treat vulvar squamous cell carcinoma. It aims to shrink tumors before surgery and may be an option for women with large or multifocal tumors.
This study tests an experimental drug called tisotumab vedotin in people with a type of vulvar cancer (squamous cell) that has spread or returned. The drug may help shrink tumors.
This trial tests if the immunotherapy drug cemiplimab can help keep advanced or recurrent vulvar cancer from growing after initial chemotherapy. Patients who have finished 4-6 cycles of platinum chemo without their cancer getting worse may be eligible.
Hear when a new Vulvar and Vaginal Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.